DGX Quest Diagnostics
- 136.140
- -0.800-0.58%
- 136.140
- 0.0000.00%
Quest Diagnostics News
Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will...
Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal
Quest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and Digital Officer
SECAUCUS, N.J., May 6, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced today that Murali Balakumar, a veteran information technolo
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
Quest Diagnostics (DGX) Inks Deal to Acquire PathAI Diagnostics
Quest Supports Expansion of Community Center and Provides No-Cost Wellness Testing to Newark Faith Community
NORTHAMPTON, MA / ACCESSWIRE / May 2, 2024 / Quest Diagnostics:At a glance:Quest worked with St. James Health in Newark to provide no-cost Blueprint for Wellness screenings during a Choose Healthy Lif
Quest Diagnostics(DGX.US) Officer Sells US$246.4K in Common Stock
$Quest Diagnostics(DGX.US)$ Officer KUPPUSAMY KARTHIK sold 1,760 shares of common stock on Apr 29, 2024 at an average price of $140 for a total value of $246.4K.Source: Announcement What is statement
Quest Diagnostics Announced A Multi-faceted Collaboration Designed To Accelerate The Adoption Of Digital And AI Pathology Innovations To Improve Quality, Speed And Efficiency In Diagnosing Cancer And Other Diseases
Quest Diagnostics Announced A Multi-faceted Collaboration Designed To Accelerate The Adoption Of Digital And AI Pathology Innovations To Improve Quality, Speed And Efficiency In Diagnosing Cancer And
Quest Diagnostics Forms Licensing Agreements With PathAI >DGX
Quest Diagnostics Forms Licensing Agreements With PathAI >DGX
Quest Diagnostics to Acquire PathAI Diagnostics >DGX
Quest Diagnostics to Acquire PathAI Diagnostics >DGX
Baird Adjusts Quest Diagnostics' Price Target to $144 From $138
Quest Diagnostics (DGX) has an average rating of outperform and price targets ranging from $136 to $160, according to analysts polled by Capital IQ. Price: 139.60, Change: +0.10, Percent Change: +0.07
Piper Sandler Reaffirms Their Hold Rating on Quest Diagnostics (DGX)
Quest Diagnostics Shares Are Trading Higher. The FDA Reportedly Finalized Its Rules That Aim to Bring Lab-developed Tests in Line With How It Oversees Other Diagnostics.
Quest Diagnostics Shares Are Trading Higher. The FDA Reportedly Finalized Its Rules That Aim to Bring Lab-developed Tests in Line With How It Oversees Other Diagnostics.
Form 144 | Quest Diagnostics(DGX.US) Officer Proposes to Sell 246.4K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 29, $Quest Diagnostics(DGX.US)$ Officer KUPPUSAMY KARTHIK intends to sell 1,760 shares of its common stock on Apr 29, with a total market value of approximately $246.4K.
Quest Diagnostics, LabCorp Climb Following FDA Testing Oversight Rule
Quest Diagnostics Up Over 5%, on Pace for Largest Percent Increase Since October 2022 -- Data Talk
Quest Diagnostics Incorporated (DGX) is currently at $141.24, up $6.99 or 5.2% --Would be highest close since Jan. 9, 2024, when it closed at $142.11 --On pace for largest percent increase since Oct
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Quest Diagnostics (DGX) and Healthcare Services (HCSG)
Quest Diagnostics: A Hold Rating Amid Solid Earnings and Strategic Caution
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight
Quest Diagnostics Is Maintained at Equal-Weight by Barclays
Quest Diagnostics Is Maintained at Equal-Weight by Barclays
Analysis
Price Target
No Data
